Regulatory Ramblings: Episode 75 - Rethinking Hong Kong’s Startup Ecosystem and Its Legal Foundations with Syed Musheer Ahmed, Joshua Chu, and David Cameron
Sunday Book Review: August 3, 2025, The Books from the EthicsVerse Library Edition
Fox on Podcasting: PodPage and Beyond: Elevating Listener Experience with Dave Jackson
What’s in Your Operating Agreement? Legal Tips for Healthcare Providers
Money-Saving Licensing Tips for Startups
Sunday Book Review: July 27, 2025, The Best Books on Economics Edition
Innovation in Compliance: The Power of Accountability and Team Culture with Gina Cotner
Compliance Tip of the Day: Rethinking Corporate AI Governance Through Design Intelligence
Daily Compliance News: July 21, 2025, The More Reasons Not to Go to China Edition
Sunday Book Review: July 20, 2025, The Best Books on Business Edition
Tips for Conducting a Trade Secret Assessment with Rob Jensen
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 242: Business Planning in Healthcare & Life Sciences with Jennifer McEwen of Maynard Nexsen
Daily Compliance News: July 14, 2025, The Secret Business Sauce-Reading Edition
Sunday Book Review: July 13, 2025, The Best Books on History Edition
Treating Compliance Like an Asset
Essential Steps to Sell Your Business
Regulatory Ramblings: Episode 72 - Cultural Roots, Belonging, and the Fear of Change: What’s Next for Inclusion?
Innovation in Compliance: LeadHERship with Linda Fisk
The Future of Supply Chains: Chris Andrassy on Using AI to Predict & Prevent Disruptions
Compliance Amidst a Global Consensus Breakdown
To help businesses, investors, and deal professionals better understand the evolving independent sponsor landscape, Robert Connolly – a partner in LP’s Corporate Practice Group and leader of LP’s Independent Sponsor team –...more
Over the past few years, we have been deeply engaged in – and have closely observed – the rapid growth of Chinese biotech companies. Despite a challenging market environment, these companies have continued to make remarkable...more
Business development companies (“BDCs”) were created by Congress in 1980 to serve as closed-end, venture capital funds for retail investors by financing small to mid-sized U.S. private companies. Since about 2004, BDC...more
Private Equity (PE) firms face pressure to deliver strong returns while managing downside risk. This necessitates a focus on performance metrics that measure value creation and overall health. However, the reporting shared by...more
The idea that investors might choose to consider certain environmental, social, and governance factors when deciding whether to buy shares of a company—a concept commonly known as ESG—continues to gain popularity with...more
The fund and asset management industry has been more focused on environmental, social and governance (“ESG”) issues in the last two years than it has been in, perhaps, the last decade....more
“ESG is really about risks,” PitchBook analysts write in PitchBook Analyst Note: ESG and the Private Markets published in April. More specifically, the authors explain that ESG factors measure and address risks that have not...more
ESG-focused investment funds raised a record amount last year – estimated at more than $50 billion in new investor money. This trend is expected to not only continue but accelerate over the next few years. ...more
In our previous alert, we described the sustainability reporting ecosystem shaping the disclosure parameters and approaches to voluntary disclosure given the lack of regulatory mandates on disclosure. ...more
This White Paper highlights the legal and regulatory considerations in the United States, the United Kingdom, the European Union, Hong Kong, and Singapore that asset managers and their institutional investor clients should...more